WESTMINSTER, Colo., Jan. 8 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. today announced that the Company will participate in the 2007 JP Morgan Healthcare Conference, to be held January 8 -11 in San Francisco. Paul L. Berns, the Company’s President and Chief Executive Officer, will give a 30-minute corporate overview on Wednesday, January 10 at 9:30 AM PT.
Live and archived web casts of the presentation will be available on the Company’s website: www.allos.com.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company has two product candidates in late-stage clinical development: EFAPROXYN (efaproxiral), a radiation sensitizer currently under evaluation in a pivotal Phase 3 trial in women with brain metastases originating from breast cancer, and PDX (pralatrexate), a novel, next generation antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also evaluating RH1, a targeted chemotherapeutic agent, in a Phase 1 trial in patients with advanced solid tumors. For additional information, please visit the Company’s website at www.allos.com
Safe Harbor Statement
The anticipated presentations will contain forward-looking statements that involve significant risks and uncertainties, including those to be discussed in the presentations and others that can be found in the “Risk Factors” section of the Company’s Form 10-K for the year ended December 31, 2005 and in the Company’s periodic reports on Form 10-Q and Form 8-K. The Company does not undertake any obligation to update any forward-looking statements contained in the anticipated presentations as a result of new information, future events or otherwise. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected.
Allos Therapeutics, Inc.
CONTACT: Jennifer Neiman Manager, Corporate Communications of AllosTherapeutics, +1-720-540-5227, jneiman@allos.com
Web site: http://www.allos.com/
